As the potential of biosimilars continues to be explored by the medical community, robust real-world evidence is becoming more important in guiding informed decision-making. This article summarised the current real-world evidence relating to biosimilar use across breast and lung cancer.
In this issue
Rate this content's potential impact on patient outcomes
Average rating / 5. Vote count:
No votes so far! Be the first to rate this content.